 Leland Shapiro
Concepts (178)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| alpha 1-Antitrypsin | 9 | 2015 | 107 | 1.440 |
Why?
| | alpha 1-Antitrypsin Deficiency | 3 | 2013 | 76 | 0.670 |
Why?
| | Shock, Septic | 1 | 2021 | 187 | 0.670 |
Why?
| | Sepsis | 1 | 2021 | 509 | 0.510 |
Why?
| | HIV Infections | 5 | 2023 | 2470 | 0.470 |
Why?
| | Cryptococcosis | 2 | 2023 | 23 | 0.370 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2021 | 1138 | 0.370 |
Why?
| | Interleukin-1beta | 3 | 2014 | 370 | 0.360 |
Why?
| | HIV-1 | 3 | 2015 | 768 | 0.340 |
Why?
| | Nitric Oxide | 2 | 2012 | 827 | 0.300 |
Why?
| | Interleukin-8 | 1 | 2009 | 238 | 0.300 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 2009 | 254 | 0.300 |
Why?
| | Interferon-gamma | 3 | 2007 | 723 | 0.290 |
Why?
| | Meningitis, Cryptococcal | 2 | 2018 | 28 | 0.280 |
Why?
| | Mycobacteriaceae | 1 | 2007 | 21 | 0.280 |
Why?
| | Receptors, CXCR4 | 1 | 2007 | 78 | 0.270 |
Why?
| | Mycobacterium Infections, Nontuberculous | 2 | 2012 | 336 | 0.270 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2007 | 112 | 0.260 |
Why?
| | Interleukin-18 | 1 | 2007 | 219 | 0.250 |
Why?
| | Interleukin-10 | 1 | 2007 | 297 | 0.250 |
Why?
| | Macrophages | 2 | 2012 | 1267 | 0.240 |
Why?
| | Anti-HIV Agents | 2 | 2007 | 668 | 0.230 |
Why?
| | Meta-Analysis as Topic | 1 | 2021 | 161 | 0.180 |
Why?
| | Cytokines | 4 | 2021 | 1843 | 0.180 |
Why?
| | Communicable Diseases, Emerging | 1 | 2020 | 28 | 0.170 |
Why?
| | Medical Errors | 1 | 2020 | 85 | 0.170 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2015 | 965 | 0.140 |
Why?
| | Patient Safety | 1 | 2020 | 277 | 0.140 |
Why?
| | Islets of Langerhans Transplantation | 2 | 2008 | 63 | 0.140 |
Why?
| | Cryptococcus | 1 | 2016 | 8 | 0.140 |
Why?
| | Antigens, Fungal | 1 | 2016 | 25 | 0.140 |
Why?
| | Clinical Trials as Topic | 1 | 2021 | 937 | 0.140 |
Why?
| | Evidence-Based Medicine | 1 | 2020 | 676 | 0.130 |
Why?
| | Middle Aged | 10 | 2018 | 26831 | 0.130 |
Why?
| | Low Density Lipoprotein Receptor-Related Protein-1 | 1 | 2015 | 14 | 0.130 |
Why?
| | Research Design | 1 | 2021 | 930 | 0.130 |
Why?
| | Adult | 11 | 2023 | 30658 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 342 | 0.120 |
Why?
| | Coronavirus Infections | 1 | 2020 | 334 | 0.120 |
Why?
| | Humans | 20 | 2023 | 115052 | 0.120 |
Why?
| | Virus Activation | 1 | 2015 | 78 | 0.120 |
Why?
| | Intraabdominal Infections | 1 | 2014 | 3 | 0.120 |
Why?
| | Hypocreales | 1 | 2014 | 8 | 0.120 |
Why?
| | Virus Replication | 2 | 2021 | 393 | 0.120 |
Why?
| | Mycoses | 1 | 2014 | 66 | 0.110 |
Why?
| | RNA, Viral | 2 | 2021 | 567 | 0.110 |
Why?
| | Male | 13 | 2018 | 55737 | 0.110 |
Why?
| | Myeloid Cells | 1 | 2014 | 127 | 0.110 |
Why?
| | NF-kappa B | 2 | 2015 | 637 | 0.100 |
Why?
| | Genetic Predisposition to Disease | 2 | 2013 | 2108 | 0.100 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2012 | 157 | 0.100 |
Why?
| | Pandemics | 1 | 2020 | 1322 | 0.100 |
Why?
| | Female | 13 | 2018 | 59619 | 0.100 |
Why?
| | Dendritic Cells, Follicular | 1 | 2011 | 5 | 0.090 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2014 | 299 | 0.090 |
Why?
| | Phosphorylation | 2 | 2012 | 1572 | 0.090 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2012 | 278 | 0.090 |
Why?
| | Monocytes | 1 | 2014 | 503 | 0.090 |
Why?
| | Dendritic Cells | 1 | 2014 | 436 | 0.090 |
Why?
| | I-kappa B Proteins | 1 | 2011 | 78 | 0.090 |
Why?
| | Enzyme Activation | 1 | 2012 | 791 | 0.090 |
Why?
| | Emphysema | 1 | 2011 | 110 | 0.090 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2023 | 2098 | 0.090 |
Why?
| | Epoprostenol | 1 | 2010 | 133 | 0.080 |
Why?
| | Blood Cells | 1 | 2009 | 38 | 0.080 |
Why?
| | Physical Endurance | 1 | 2010 | 231 | 0.080 |
Why?
| | Staphylococcus epidermidis | 1 | 2009 | 71 | 0.080 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 797 | 0.080 |
Why?
| | Islets of Langerhans | 1 | 2014 | 729 | 0.070 |
Why?
| | Placebos | 1 | 2007 | 198 | 0.070 |
Why?
| | Cell Line | 1 | 2012 | 2645 | 0.070 |
Why?
| | Serine Proteinase Inhibitors | 1 | 2007 | 35 | 0.070 |
Why?
| | Double-Blind Method | 2 | 2010 | 1665 | 0.070 |
Why?
| | Immune Tolerance | 1 | 2008 | 329 | 0.070 |
Why?
| | Diabetes Mellitus, Type 1 | 3 | 2014 | 3247 | 0.070 |
Why?
| | Antihypertensive Agents | 1 | 2010 | 430 | 0.070 |
Why?
| | Aged | 6 | 2018 | 19122 | 0.070 |
Why?
| | Transplantation Tolerance | 1 | 2005 | 31 | 0.060 |
Why?
| | Risk Factors | 4 | 2023 | 8642 | 0.060 |
Why?
| | Cells, Cultured | 2 | 2011 | 3896 | 0.060 |
Why?
| | Case-Control Studies | 3 | 2018 | 3015 | 0.060 |
Why?
| | Cell Proliferation | 1 | 2011 | 2191 | 0.060 |
Why?
| | Phenotype | 2 | 2012 | 2815 | 0.060 |
Why?
| | Apoptosis | 1 | 2011 | 2366 | 0.050 |
Why?
| | Propensity Score | 1 | 2023 | 224 | 0.050 |
Why?
| | Mice | 3 | 2012 | 14928 | 0.050 |
Why?
| | History, 17th Century | 1 | 2020 | 15 | 0.040 |
Why?
| | Cross-Sectional Studies | 1 | 2010 | 4411 | 0.040 |
Why?
| | History, 21st Century | 1 | 2020 | 161 | 0.040 |
Why?
| | History, 20th Century | 1 | 2020 | 267 | 0.040 |
Why?
| | Hypertension, Pulmonary | 1 | 2010 | 1736 | 0.040 |
Why?
| | Mortality | 1 | 2020 | 287 | 0.040 |
Why?
| | Animals | 4 | 2012 | 31868 | 0.040 |
Why?
| | Hyponatremia | 1 | 2018 | 37 | 0.040 |
Why?
| | Betacoronavirus | 1 | 2020 | 253 | 0.040 |
Why?
| | Cohort Studies | 1 | 2007 | 4904 | 0.040 |
Why?
| | Inflammation | 1 | 2007 | 2485 | 0.030 |
Why?
| | Retrospective Studies | 2 | 2018 | 12548 | 0.030 |
Why?
| | Prospective Studies | 1 | 2007 | 6232 | 0.030 |
Why?
| | Hospitals, University | 1 | 2016 | 170 | 0.030 |
Why?
| | Analysis of Variance | 2 | 2011 | 1229 | 0.030 |
Why?
| | Time Factors | 2 | 2021 | 6142 | 0.030 |
Why?
| | Clathrin | 1 | 2015 | 27 | 0.030 |
Why?
| | Young Adult | 3 | 2016 | 10498 | 0.030 |
Why?
| | Academic Medical Centers | 1 | 2018 | 412 | 0.030 |
Why?
| | Lysosomes | 1 | 2015 | 123 | 0.030 |
Why?
| | Cytosol | 1 | 2015 | 208 | 0.030 |
Why?
| | Immunocompromised Host | 1 | 2016 | 196 | 0.030 |
Why?
| | Hearing Loss | 1 | 2018 | 183 | 0.030 |
Why?
| | Endocytosis | 1 | 2015 | 151 | 0.030 |
Why?
| | Adrenal Cortex Hormones | 1 | 2018 | 499 | 0.030 |
Why?
| | Endosomes | 1 | 2015 | 124 | 0.030 |
Why?
| | Microbiological Techniques | 1 | 2014 | 29 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2018 | 1435 | 0.030 |
Why?
| | Antifungal Agents | 1 | 2014 | 129 | 0.030 |
Why?
| | Toll-Like Receptors | 1 | 2014 | 166 | 0.030 |
Why?
| | Peritoneal Dialysis | 1 | 2014 | 83 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2018 | 1812 | 0.030 |
Why?
| | Logistic Models | 1 | 2018 | 1839 | 0.030 |
Why?
| | Funnel Chest | 1 | 2012 | 20 | 0.030 |
Why?
| | Adipokines | 1 | 2012 | 43 | 0.030 |
Why?
| | Gene Frequency | 1 | 2013 | 483 | 0.030 |
Why?
| | Proliferating Cell Nuclear Antigen | 1 | 2011 | 49 | 0.020 |
Why?
| | PPAR alpha | 1 | 2011 | 52 | 0.020 |
Why?
| | Prevalence | 1 | 2018 | 2255 | 0.020 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2011 | 57 | 0.020 |
Why?
| | Down-Regulation | 1 | 2014 | 599 | 0.020 |
Why?
| | Lung Diseases | 1 | 2018 | 703 | 0.020 |
Why?
| | Polyubiquitin | 1 | 2011 | 7 | 0.020 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2011 | 119 | 0.020 |
Why?
| | NF-KappaB Inhibitor alpha | 1 | 2011 | 52 | 0.020 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2011 | 140 | 0.020 |
Why?
| | NF-kappa B p50 Subunit | 1 | 2011 | 25 | 0.020 |
Why?
| | Disease Susceptibility | 1 | 2012 | 316 | 0.020 |
Why?
| | Ubiquitination | 1 | 2011 | 86 | 0.020 |
Why?
| | Caspase 3 | 1 | 2011 | 237 | 0.020 |
Why?
| | Transcription Factor RelA | 1 | 2011 | 83 | 0.020 |
Why?
| | Coculture Techniques | 1 | 2011 | 201 | 0.020 |
Why?
| | Smoke | 1 | 2011 | 127 | 0.020 |
Why?
| | Adolescent | 3 | 2014 | 17866 | 0.020 |
Why?
| | PPAR gamma | 1 | 2011 | 184 | 0.020 |
Why?
| | Scoliosis | 1 | 2012 | 181 | 0.020 |
Why?
| | Hypertension | 1 | 2018 | 1058 | 0.020 |
Why?
| | RNA Interference | 1 | 2011 | 437 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2010 | 372 | 0.020 |
Why?
| | Kidney Failure, Chronic | 1 | 2014 | 489 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2011 | 499 | 0.020 |
Why?
| | Pulmonary Alveoli | 1 | 2011 | 374 | 0.020 |
Why?
| | Adipose Tissue | 1 | 2012 | 558 | 0.020 |
Why?
| | Treatment Outcome | 2 | 2014 | 9123 | 0.020 |
Why?
| | Up-Regulation | 1 | 2011 | 812 | 0.020 |
Why?
| | Mice, Inbred C57BL | 2 | 2008 | 4718 | 0.020 |
Why?
| | Transplantation, Homologous | 1 | 2008 | 390 | 0.020 |
Why?
| | Colorado | 1 | 2016 | 4089 | 0.020 |
Why?
| | Lymph Nodes | 1 | 2008 | 422 | 0.020 |
Why?
| | Walking | 1 | 2010 | 424 | 0.020 |
Why?
| | Macrophage Inflammatory Proteins | 1 | 2005 | 12 | 0.020 |
Why?
| | Chemokine CCL3 | 1 | 2005 | 15 | 0.020 |
Why?
| | Chemokine CCL4 | 1 | 2005 | 21 | 0.020 |
Why?
| | Granulocytes | 1 | 2005 | 77 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2016 | 6357 | 0.020 |
Why?
| | Mice, Inbred DBA | 1 | 2005 | 173 | 0.020 |
Why?
| | Body Mass Index | 1 | 2012 | 1967 | 0.020 |
Why?
| | Child | 2 | 2014 | 18409 | 0.020 |
Why?
| | Cell Movement | 1 | 2008 | 866 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2011 | 2716 | 0.010 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2005 | 353 | 0.010 |
Why?
| | Rats | 1 | 2011 | 4973 | 0.010 |
Why?
| | Killer Cells, Natural | 1 | 2005 | 383 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2010 | 2551 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2011 | 3545 | 0.010 |
Why?
| | United States | 1 | 2018 | 12227 | 0.010 |
Why?
| | Heart Failure | 1 | 2014 | 1962 | 0.010 |
Why?
| | Interleukin-1 | 1 | 2005 | 970 | 0.010 |
Why?
| | Diabetes Mellitus | 1 | 2008 | 906 | 0.010 |
Why?
| | Biomarkers | 1 | 2010 | 3419 | 0.010 |
Why?
| | Exercise | 1 | 2010 | 1644 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2008 | 2329 | 0.010 |
Why?
|
|
Shapiro's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|